EMA – Page 12 – Pharma.Tips

Lead candidate fails downstream criteria before IND-enabling studies – data package strengthening approach

Investigating the Failure of a Lead Candidate Before IND-Enabling Studies In the intricate world of drug development, a common yet significant hurdle is the failure of a lead candidate to…

Lead candidate fails downstream criteria during portfolio review – how to avoid late-stage attrition

Addressing Failures of Lead Candidates During Portfolio Review to Mitigate Late-Stage Attrition The challenge of ensuring that lead candidates pass downstream criteria during portfolio reviews is increasingly critical in the…

Lead candidate fails downstream criteria during portfolio review – risk mitigation strategy

Mitigating Risks When a Lead Candidate Fails Downstream Review Criteria In the complex landscape of pharmaceutical development, a lead candidate might fail to meet the downstream criteria during a portfolio…

Reproducibility issues in screening data before IND-enabling studies – impact on IND success probability

Addressing Reproducibility Challenges in Screening Data Prior to IND-Enabling Studies Reproducibility issues in screening data can significantly undermine the potential for success in investigational new drug (IND) submissions. When preclinical…

Target validation uncertainty during early discovery – data package strengthening approach

“`html Addressing Target Validation Uncertainty in Early Discovery: A Data Package Strengthening Approach In the current landscape of drug discovery, navigating the intricacies of target validation is paramount. As companies…

ADME liabilities identified late during early discovery – data package strengthening approach

Addressing Late-Identified ADME Liabilities in Early Drug Discovery: A Comprehensive Investigation Approach In the fast-paced world of pharmaceutical research, early identification of ADME (Absorption, Distribution, Metabolism, and Excretion) liabilities is…

ADME liabilities identified late before IND-enabling studies – how to avoid late-stage attrition

“`html Minimizing Late-Stage ADME Liabilities in IND-Enabling Studies In the complex landscape of pharmaceutical development, late-stage attrition due to pharmacokinetic parameters can pose significant risks. Identifying ADME (Absorption, Distribution, Metabolism,…

ADME liabilities identified late during translational assessment – data package strengthening approach

Late-Identified ADME Liabilities and Strategies for Strengthening Data Packages Identifying ADME (Absorption, Distribution, Metabolism, and Excretion) liabilities late in the drug development process can pose significant challenges. Such issues can…

Lead candidate fails downstream criteria during regulatory interaction preparation – risk mitigation strategy

“`html Investigating Failures of Lead Candidates During Regulatory Preparation Advancing a lead candidate in drug discovery through regulatory preparation is a pivotal moment in the drug development lifecycle. When a…

Poor hit-to-lead progression during early discovery – how to avoid late-stage attrition

Investigating Poor Hit-to-Lead Progression in Early Drug Discovery: A Structured Approach In the pharmaceutical industry, the transition from hit to lead compounds during early drug discovery is critical. Poor hit-to-lead…

Lead candidate fails downstream criteria before IND-enabling studies – how to avoid late-stage attrition

Addressing Failures in Lead Candidate Criteria Prior to IND-Enabling Studies In the drug development landscape, the failure of a lead candidate during downstream criteria assessment can be a significant setback,…

Reproducibility issues in screening data during translational assessment – decision framework regulators expect

Addressing Reproducibility Issues in Screening Data During Translational Assessment Reproducibility issues in screening data can significantly impact the trajectory of drug development, particularly during the critical phase of translational assessment…